Galenika: 78 years dedicated to people and faithful to health

Alma Krilic-Hrapovic

Interview with Alma Krilic-Hrapovic, regional sales development manager in Galenika

Further expansion of international markets, digitization of operations and focus on development are on the agenda of the pharmaceutical company Galenika for 2023. The regional pharmaceutical leader, as part of the Brazilian NC Group, has been continuing the tradition of successfully providing value to product users, partners and employees since 2017. With the regional sales development manager at the Galenika company, Alma Krilic-Hrapovic, we talk about the results achieved in the past year, about their regional role as a corporately responsible company that invests in health preservation, as well as about the implemented projects and future plans.

What would you take away from Galenika's operations in 2022?

Although 2022 was a challenging year during a period of turbulence in the global market, I can proudly say that it was a successful one for Galenica. Continuous investments, modernization, as well as the commitment of the team that shares the common vision for the future of Galenika contribute to success and growth.

Expanding the portfolio with modern, high-quality products demonstrates innovation and is a prerequisite for company growth. In this way, Galenika always provides users with relevant and highest quality products, in line with their modern needs. For illustration – in 2022 we launched 18 new products in North Macedonia and 61 in the markets in the region where we operate (Serbia, Bosnia and Herzegovina, Montenegro and Albania).

Galenica has a strategic cooperation with its sister company from Brazil – EMS, which is also part of the NC Group, and which is the number one pharmaceutical company in Brazil and one of the largest in all of Latin America, which significantly strengthens the company and its operations. I will give you an example: in 2022, the research and development service of Galenika, in a strategic partnership with EMS, successfully carried out the technology transfer of five products of the latest generation of generic drugs.

We operate in 15 international markets, including EU countries, we have opened offices in Croatia and Slovenia, and this international expansion clearly proves the highest standards and quality we apply, as well as trust and relevance. I am pleased to say that Galenica has proven its ability to compete globally with its expertise and quality in the pharmaceutical industry.

This clearly shows the strength of our 78-year heritage, but also a focus on the future and development, where we are dedicated to people and health at every moment.

Last year, you significantly expanded your product portfolio in the region, but also in Macedonia. What are the new products available for the citizens of North Macedonia?

We are constantly improving and expanding our product portfolio. Among other things, since last year the citizens of North Macedonia have had access to borderline products for the youngest Vitup Baby D3, Vitup Baby D3 + K1, Vitup Baby D3 + DHA Omega, as well as Oligogal Magnesium, Oligogal Iron, Floniivin Boulardii, Flonivin Kids Immuno, Flonivin Forte, as well as the enzyme preparation Digestal.

Galenika

At the end of 2022, Galenika presented a large regional survey on the use of medicines in the markets of North Macedonia, Bosnia and Herzegovina and Serbia. Can you say more about the research and compare the results of the three markets?

With this research, Galenika aimed to contribute through relevant data to raising awareness of the importance of prevention and preserving the health of citizens in the three mentioned countries. As well as for the further expansion of our portfolio with high-quality products that will best meet the current needs of the user. Galenika always strives to provide additional value to the market, and we consider the knowledge from this research to be a value that will focus on what is most valuable to us, which is health and its preservation. It is interesting how similar the numbers are in all three markets, which illustrates the equal circumstances under which the modern man lives, so the habits of the citizens regarding the use of medicines and the challenges they have with health are very similar.

Citizens of North Macedonia, Bosnia and Herzegovina and Serbia have similar products in their home pharmacies. For example, 80 percent of citizens in North Macedonia usually have products in their home pharmacies that are regularly issued without a doctor's prescription, in Bosnia and Herzegovina – 85 percent, and in Serbia – 84 percent. Most often these are medicines to reduce high temperature (74%) and for cold, cough or sore throat (70%).

What results do the results of the research indicate when it comes to the chronic health problems of the citizens?

It is similar with the data on acute and chronic problems of citizens from all three countries. High on the scale of chronic health problems are cardiovascular diseases, and on average in all three countries citizens use about 3 medicines for chronic problems. The most common acute problems are headaches, pain in the back and limbs, as well as respiratory infections. If we look at the research for North Macedonia, slightly more than half of the population have habits that should maintain their health or strengthen their immunity. About 55 percent of respondents declared that they regularly go for a walk or do recreational sports, and about 48 percent prefer supplements with vitamins and minerals or preparations specially designed to strengthen immunity. But these percentages do not differ significantly in BiH and Serbia. I would add that for us the data obtained through this research are valuable and once again underline the importance of raising awareness about the active prevention of diseases and I want to emphasize that this research is a kind of support for the Galenika Company to preserve the health of all citizens in these three countries.

What are you particularly proud of in relation to Galenika's work in the previous year?

Galenika demonstrates its ongoing commitment to responsible business and the wider social community by supporting socially responsible projects, as we believe they reflect the importance of both society as a whole and each individual. We are proud to be active through various socially responsible projects throughout the region. For example, last year in North Macedonia we supported the holding of the largest urban and international sports event, the Skopje Marathon, in which over 8.500 professional and amateur competitors from 47 countries participated. This support reflects our commitment to promoting healthy lifestyles. We also organized a concert for the youngest in the City Park in Skopje, where elementary school students could show their creative abilities and their affinity for sports through games and fun.

What are Galenia's priorities in 2023?

It has three priorities: people, health and sustainable business.

We are focused on people and the expansion of our portfolio, as well as the continuous delivery of the necessary quantities of high-quality products. It sounds simple, but in these global conditions it can be challenging and requires great efforts, along with expertise and dedication. For example, in 2023, in cooperation with our sister company from Brazil – EMS, we have already started the implementation of technology transfer for an additional 5 products of the newer generation of generic drugs.

Our goal is double-digit growth, further internationalization of business and digitization based on relevant business data collected from the market, innovation and business agility.


Sponsored post

Dear reader,

Our access to web content is free, because we believe in equality in information, regardless of whether someone can pay or not. Therefore, in order to continue our work, we ask for the support of our community of readers by financially supporting the Free Press. Become a member of Sloboden Pechat to help the facilities that will enable us to deliver long-term and quality information and TOGETHER let's ensure a free and independent voice that will ALWAYS BE ON THE PEOPLE'S SIDE.

SUPPORT A FREE PRESS.
WITH AN INITIAL AMOUNT OF 60 DENARS

Video of the day